Yuzuriha T, Den R, Yumoto Y, Aoshima K, Inoue S, Chikashima H. Burden of illness for alcohol dependence using health insurance claims database in Japan. Nihon Arukoru Yakubutsu Igakkai 2019, Poster. October 4-6, 2019, Sapporo, Japan (in Japanese).

Liu G, Kobayashi M, Pizzi L T. Drug Pricing and Value Perspectives on the US versus Asia. ISPOR 2019, New Orleans, LA, USA. ISPOR Forum. May 20, 2019.

Kusumi I, Inoue S, Baba K, Nosaka T, Anzai T. Inspection of the cardiovascular event onset risk by therapeutic drug for Schizophrenia：Cohort study using medical information database. The 115th Annual Meeting of the Japanese Society of Psychiatry and Neurology. June 20-22, 2018, Niigata, Japan. (in Japanese)

Murata T, Suzukamo Y, Shiroiwa T, Taira N, Shimozuma K. RESPONSE SHIFT EFFECT ON QUALITY OF LIFE IN RANDOMIZED CONTROL TRIAL OF TAXANE VERSUS S-1 FOR METASTATIC BREAST CANCER PATIENTS (SELECT-BC): STRUCTURAL QUATION MODELING. ISPOR Europe, Barcelona, Spain. Poster Presentation. Nov 14, 2018.

Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova AV, Chin R, Hirase T, Shibahara T, Hayashi N, Kansal A, Kaspers S, Okamura T. COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL. ISPOR Europe, Barcelona, Spain. Poster Presentation. Nov 13, 2018.

Kobayashi M．Value-based Approach [49] Selection of Technology for Comparison Decides Winners and Losers: Different aspects from clinical research -Efficiency Frontier-. Monthly Medical Information Express. 2022; 5:78-81 (in Japanese)

Kobayashi M．Value-based Approach [48] To understand analysis guideline, consider ICER in the cost-effectiveness analysis. Learning the basis of ICER. Monthly Medical Information Express. 2022; 4:86-88 (in Japanese)

Kobayashi M．Value-based Approach [47] To understand analysis guideline, Consider cost-effectiveness in the cost-effectiveness plane. Monthly Medical Information Express. 2022; 3:76-78 (in Japanese)

Kobayashi M．Value-based Approach [46] Chapter on Health economic evaluation added to Minds clinical guidelines development manual. Introduction to analysis guideline(22) Health economic evaluation in clinical guidelines? Monthly Medical Information Express. 2022; 1:84-86 (in Japanese)

Kobayashi M．Value-based Approach [45] Medical Devices, first to be subjected to the cost-effectiveness assessment. Introduction to analysis guideline (21) Considering how to deal with HTA for medical devices. Monthly Medical Information Express. 2021; 12:82-85 (in Japanese)

Inoue S. Chapter 9. Cost-effectiveness analysis of drugs and  application to market access. Section 2. Cost-effectiveness analysis of drugs and utilization of drug price application. Technical Information Institute co,. LTD. 2019. (in Japanese)

Inoue S. Chapter 6. Health care, economic and value of self-injection, dropping to the doctors and the patient needs and product development for the valuation of self-injection. Self-injection to think from Section 2 medical economic point of view medical fee points. (Regulatory Science).2016. (in Japanese)

Kobayashi M. Model analysis in the medical economic evaluation. Basic medical economic evaluation -to understand cost-effectiveness definitely- (Regulatory Science).2015, Page.103-125.(in Japanese)

Kobayashi M. Specific method of utilizing Pharmacoeconomics. Technical Information Institute co,. LTD. (Nagase T et al eds). 2014. (in Japanese).2014.

Inoue S. Development strategy on the basis of the real condition and clinical condition, a mechanism of the treatment of sepsis. Technical Information Institute co,. LTD. (Hayakawa M et al eds). 2013. (in Japanese)